Vaccine Congress Washington Agenda

 

 

 

World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speaker, 10 conferences, 8 workshops, 100+ exhibitors providing the most exciting vaccine event on the planet. It is carefully curated by an experienced team who are plugged into a global network. Our presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism and insight. 

 

BOOK BY APRIL 5 & SAVE

 

  

Washington DC, 14 - 17 April 2019

Schedule

Create your personal agenda –check the favourite icon

Apr 1508:20
Conference pass

Chair’s opening remarks

Keynotes
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Apr 1508:30
Conference pass

Strengthening the effectiveness of national, state & local efforts to improve the uptake of HPV vaccination

Keynotes
Apr 1508:45
Conference pass

Plenary keynote insights: What direction will vaccines take to ensure safety and mass immunization

Keynotes
  • Vaccine Research and Development in the Public Sector
  • What kind of regulatory and political support can we expect?
  • Prevention and pre-prepared efforts to ensure our current and future safety
  • Vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development
Apr 1509:45
Conference pass

How can we be better prepared for disease X?

Keynotes
  • What kind of regulatory and political support can we expect?
  • Prevention and pre-prepared efforts to ensure our current and future safety
  • Vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development
Apr 1511:45
Conference pass
Apr 1511:45
Conference pass

Developing more effective vaccines for emerging/re-emerging pandemic threats

Keynotes
Dr James F. Cummings, MD, President, ICON Government and Public Health Solutions – title TBC
Apr 1511:45
Conference pass
Apr 1511:45
Conference pass

Identifying the ideal vaccine research site – lessons learned from the field

Keynotes
Senior representative, PPD
Jason Berg, Director, Project Management, PPD
Apr 1511:45
Conference pass

Immune Profiling - capturing the complexity of immune responses to vaccines and infections

Keynotes
Apr 1511:45
Conference pass
Apr 1511:45
Conference pass

Oncology – applying precision medicine and informatics to find the best treatment option for each patient

Keynotes
Apr 1511:45
Conference pass

Pediatric Vaccine Trials – Recruitment and Retention

Keynotes
Apr 1511:45
Conference pass

Replacing antiquated assays with rapid viral vaccine Infectivity measurements and process analytical technologies (PAT)

Keynotes
Apr 1511:45
Conference pass

Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?

Keynotes
Dr Nathalie Garcon, CSO & CEO, Bioaster
Apr 1511:45
Conference pass

Seasonal vaccine studies: Critical success factors

Keynotes
Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research – title TBC
Apr 1511:45
Conference pass
Apr 1511:45
Conference pass

When limited patient resources meet unlimited immunotherapy combinations—the strategies to develop clinical IO agents in platform studies

Keynotes
Apr 1514:40
Conference pass

The role of vaccines to combat antibiotic-microbial resistance

Keynotes
  • What can we do to manage AMR? The mis-use of Abx in bacterial and viral infections
  • How vaccine regulatory and access policies can be used to strengthen utilization of vaccines as a component of multi-pronged strategies that governments should take in their national action plans to address AMR
  • The need for a holistic and collaborative strategy including cross species considerations
Apr 1515:30
Conference pass

Fire chat: The future of the vaccine business from the executives

Keynotes
  • What vaccines will they invest in and why
  • How will we translate data heavy tools into translational precision medicines?
  • Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs?
  • Should it be industry’s responsibility to help address vaccine hesitancy?
Apr 1517:00
Conference pass

The continuing instrumental role of NGOs: Making the impossible, achievable

Plenary afternoon day 1
  • What global market trends can we expect in the next 10 years? What does this mean for vaccines?
  • Impact of emerging diseases, AMR and measles outbreaks
  • Ongoing efforts towards developing world diseases and child health
  • Strengthening of primary health care systems
Apr 1517:00
Conference pass

One Health pharma strategy update

ONE HEALTH
  • Examining the strategic context, rationale and case for investing in One Health
  • How are the veterinary pharma companies working towards a implementing a One Health approach?
Apr 1517:50
Conference pass

The resurgence of immuno-oncology – Can they hold their promise?

Plenary afternoon day 1
  • How will recent breakthroughs in immuno-oncology shape the way we design cancer vaccines and combinational treatments?
  • Are our expectations vs the reality of immunotherapies working aligned?
  • How can we better characterize post-treatment analysis of anti-tumor immune responses to develop more effective immunotherapy approaches?
  • Advancements in personalized neoantigen vaccines and novel targets
Apr 1517:50
Conference pass

Operational framework for strengthening human & animal public health systems at their interface

ONE HEALTH
  • What tools and resources from the human health, animal health, and disaster risk reduction sectors can facilitate multi-sectoral coordination?
  • Strategy for appropriate One Health entry points and a pathway to the prevent-detect-respond-recover spectrum of preparedness
  • What public health system changes do we need to truly facilitate a One Health approach?

Create your personal agenda –check the favourite icon

Apr 1609:00
Conference pass
Apr 1609:00
Conference pass

Chair's opening remarks

Cancer & Immunotherapy Vaccines Conference
Apr 1609:00
Conference pass

Chair’s opening remarks

Veterinary Vaccines Conference
Apr 1609:00
Conference pass

Chair’s opening remarks

Vaccine Partnerships Conference
Barry Eisenstein, Chair, Scientific Advisory Board, CARB-X
Apr 1609:10
Conference pass

The immune setpoint: Baseline immune status predicts vaccine response

Immune Profiling Conference
Dr Stacey Wooden, Scientific Advisor, The Human Vaccines Project
Apr 1609:10
Conference pass

How can we take the next step in cancer immunotherapy?

Cancer & Immunotherapy Vaccines Conference
Apr 1609:10
Conference pass

Universal flu: are we any closer to finding the “holy “grail”? The Grand Challenge

Influenza and Respiratory Vaccines
  • 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that’s translational to a universal solution
  • The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities
  • Newest research in universal influenza vaccines and their potential impact on the flu market
Apr 1609:10
Conference pass

From development to deployment: Challenges and achievements in creating an Ebola vaccine

Emerging and Re-emerging Diseases
Apr 1609:10
Conference pass

HIV vaccines in Clinical Trials

Clinical Development and Trials Conference
- Immunology and virology of HIV-1 infection and developing novel vaccine strategies
Apr 1609:10
Conference pass

New Models: How are smaller product development organizations (biotechs/non-profit/academics) manufacturing vaccine products for early and exploratory PoC clinical trials? Are larger Biopharma adaptin

Bioprocessing & Manufacturing Conference
  • How are non-profits and academics de-risking earlier staged vaccine research before further development?
  • Strategy in collaborative models
  • A new shift in how vaccines are developed, how does this compare to 10 years ago? Is there a new emphasis on testing in humans earlier?
  • Pharma vision – is there a growing gap in end to end processing expertise?
Apr 1609:10
Conference pass

Structural vaccinology and its potential impact on the next generation of veterinary vaccines

Veterinary Vaccines Conference
Apr 1609:10
Conference pass

Can vaccines lessen the burden of antibiotic resistance?

Vaccine Partnerships Conference
-Who is CARB-X-What vaccines programs they are supporting -What they are looking for in a partner, public-private partnerships
Barry Eisenstein, Chair, Scientific Advisory Board, CARB-X
Apr 1609:10
Conference pass

Supporting vaccine distribution with a stability budget

Supply & Logistics Conference
Apr 1609:40
Conference pass

Precision vaccines: Bringing precision medicine to vaccinology

Immune Profiling Conference
Apr 1609:40
Conference pass
Apr 1609:40
Conference pass

Development pathway to universal influenza vaccination

Influenza and Respiratory Vaccines
Apr 1609:40
Conference pass

Bridging the adjuvants gap between vet & human

Veterinary Vaccines Conference
Apr 1609:40
Conference pass

Strategies to enhance vaccine acceptance in future generations

Vaccine Safety Conference
  • How have non-medical exemptions affected vaccine uptake in the US?
  • The vaccine education project: Laying the groundwork to ensure children and young adults are more accepting of vaccines in the future – what are the reasons that people are influenced by the anti-vaccine movement?
  • Developing a vaccine education curriculum for physicians to increase vaccine acceptance
  • What is the current and future role of digital/social media in shaping public perception around vaccination?
  • How can the media be used as a tool to aid scientists in getting out their message accurately? How can scientists communicate with journalists more effectively?
Apr 1609:40
Conference pass

Workforce planning at the center for vaccine innovation and access PATH - Lessons learned

Supply & Logistics Conference
Apr 1609:45
Conference pass

FireChat 2 – Reducing Bacterial Adherence May Lessen Morbidity and Mortality caused by Urinary Tract Infections

Vaccine Partnerships Conference
Apr 1609:55
Conference pass

VRC Ebola trials update: Vaccines and mAbs

Emerging and Re-emerging Diseases
LCRD Martin Gaudinski, LCRD, Public Health Service, Medical Director at Vaccine Research Center Clinical Trials Program, National Institutes of Health
Apr 1610:00
Conference pass

FireChat 3 – A combination, live attenuated, oral vaccine against Shigella and ETEC infections

Vaccine Partnerships Conference
Apr 1610:10
Conference pass

Explainable artificial intelligence (XAI) to gain insights into vaccine action

Immune Profiling Conference
Apr 1610:10
Conference pass

Challenges in identification of cancer neoantigens: lessons from mouse models and a Phase 1 trial in patients with advanced ovarian cancers

Cancer & Immunotherapy Vaccines Conference
  • Most potential antigens identified in silico are not active in vivo
  • Algorithms for prediction of good CTL epitopes in viral and model antigens are generally not predictive of good anti-cancer response
  • CD8 response as measured ex vivo is not predictive of anti-tumor response (i.e. tumor regression) in vivo
  • New rules for prediction are suggested
  • A Phase 1 trial in patients with advanced ovarian cancers is ongoing
Apr 1610:10
Conference pass

Growth of vaccine studies opportunities in Africa and Asia

Influenza and Respiratory Vaccines
Dr Cheryl Keech, Executive Medical Director, PPD
Jason Berg, Director, Project Management, PPD
Apr 1610:10
Conference pass

Executing multi-international trials and research for infectious diseases at WRAIR

Emerging and Re-emerging Diseases
Apr 1610:10
Conference pass

Seasonal influenza vaccine efficacy studies: Lessons learned from 3 global studies

Clinical Development and Trials Conference
Apr 1610:10
Conference pass

The application of QbD principles from preformulation to tech transfer in vaccine development

Bioprocessing & Manufacturing Conference
Apr 1610:10
Conference pass

Brexit and its potential impact on clinical supply chain

Supply & Logistics Conference
Apr 1611:40
Conference pass

Innate immune profiling for Dengue infection & vaccination

Immune Profiling Conference
Dr Ana Fernandez-Sesma, Chair, Human Immunology Project Consortium & Professor, Icahn School Of Medicine, Mount Sinai
Ana Fernandez-Sesma, Professor, Mount Sinai
Apr 1611:40
Conference pass

Inhibitory T cell responses are identified using the ATLASTM platform technology: implications for cancer immunotherapy

Cancer & Immunotherapy Vaccines Conference
Apr 1611:40
Conference pass

Ph3 efficacy results a VLP influenza vaccine

Influenza and Respiratory Vaccines
Senior representative, Medicago
Apr 1611:40
Conference pass

Developing a single-shot vaccine against Chikungunya: VLA 1553 Phase 1 initial results and next steps

Emerging and Re-emerging Diseases
Apr 1611:40
Conference pass

Genetic Stability Studies: Could Process Parameters Change Your Virus?

Bioprocessing & Manufacturing Conference
Apr 1611:40
Conference pass

Animal viruses engineered as human vaccines against infections of animals transmissible to humans

Veterinary Vaccines Conference
Apr 1611:40
Conference pass
Apr 1611:40
Conference pass

Working with multiple partners to contain an outbreak – Ebola outbreak case study

Supply & Logistics Conference
Apr 1611:55
Conference pass

Virus like particles for effective antigen delivery in therapeutic vaccines

Cancer & Immunotherapy Vaccines Conference
Apr 1611:55
Conference pass

Development of synthetic enteroviral vaccines

Bioprocessing & Manufacturing Conference
Apr 1611:55
Conference pass

FireChat 5 – Developing infectious disease vaccine using mRNA technologies for pharmacologically optimized protein coding RNA

Vaccine Partnerships Conference
Apr 1612:10
Conference pass

Divergent immune responses to West Nile virus

Immune Profiling Conference
Apr 1612:10
Conference pass

Application of the 3M Microneedle delivery system for effective caner immunotherapy

Cancer & Immunotherapy Vaccines Conference
Apr 1612:10
Conference pass

Cheetah Pace for Premium Vaccine Clinical Assay Development: FLU HA Case Study

Influenza and Respiratory Vaccines
Apr 1612:10
Conference pass

Advancements towards first commercial Chikungunya vaccine

Emerging and Re-emerging Diseases
Senior representative, Nipah Project Leader, PATH
Apr 1612:10
Conference pass

Conceptualizing issues around routes of inoculation VS immunological response

Clinical Development and Trials Conference
Apr 1612:10
Conference pass

Outsource manufacturing of your vaccine candidate: The do’s and don’ts

Bioprocessing & Manufacturing Conference
Senior representative, Wacker Biotech
Apr 1612:10
Conference pass

Incorporating precision vaccines into swine health: The use of RNA tech Sequivity to develop custom vaccines targeting specific diseases in individual herds

Veterinary Vaccines Conference
Apr 1612:10
Conference pass

FireChat 6 – Developing novel cancer immunotherapies based on optimized, antigen-encoding and complexed mRNA molecules

Vaccine Partnerships Conference
Apr 1612:10
Conference pass

Using supply chain simulation modeling to inform vaccine technology development

Supply & Logistics Conference
Apr 1612:25
Conference pass

Overview of Neon’s approach to the development of personalized cancer immunotherapies

Cancer & Immunotherapy Vaccines Conference
Apr 1612:25
Conference pass

Applying knowledge from HIV to develop a Lassa vaccine

Emerging and Re-emerging Diseases
Rerserved for IAVI
Apr 1612:25
Conference pass

FireChat 7 – A Single Intranasal Immunization with M2SR (M2 deletion, single replication) Vaccine Protects Against a Substantially Drifted H3N2 Influenza Virus in Human Challenge Study

Vaccine Partnerships Conference
Apr 1612:40
Conference pass

Systems-level profiling of the influenza vaccination response

Immune Profiling Conference
Apr 1612:40
Conference pass

DCVax® personalized immune therapies for cancer

Cancer & Immunotherapy Vaccines Conference
Apr 1612:40
Conference pass

Ph2 oral vaccine for protection against influenza challenge in humans

Influenza and Respiratory Vaccines
Apr 1612:40
Conference pass

DNA-launched live-attenuated flavivirus vaccines

Emerging and Re-emerging Diseases
Apr 1612:40
Conference pass

Comparison of Zika Virus Neutralization Assay Platforms: PRNT and RVP

Clinical Development and Trials Conference
Brent Seaton, Associate Director, Science, Q² Solutions
Apr 1612:40
Conference pass

Accelerating innovation for safe, robust and cost effective vaccine development and manufacturing in developing markets

Bioprocessing & Manufacturing Conference
  • Latest trends and key considerations in vaccine development and manufacturing in emerging markets.
  • Advancing bioprocessing technologies to serve domestic needs, more simply and affordably
  • Single use systems and flexible and scalable technologies
  • A case study how single use involves vaccine process development on a virus-like particles (VLPs) vaccine candidate in China
Senior representative, Sartorius-Stedim
Apr 1612:40
Conference pass

Nanovaccines and nano-adjuvants for efficient vaccination programs

Veterinary Vaccines Conference
Apr 1612:40
Conference pass

Getting to market faster – economics of new product supply

Supply & Logistics Conference
Apr 1612:55
Conference pass

Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered

Influenza and Respiratory Vaccines
Apr 1612:55
Conference pass

ExpreS2 – An insect cell-based vaccine production system suitable for difficult-to-express proteins

Emerging and Re-emerging Diseases
Apr 1612:55
Conference pass

NanoQuil - a novel next-generation saponin adjuvant

Clinical Development and Trials Conference
Laurent Duroux, Senior Scientist, Brenntag As
Apr 1614:40
Conference pass

Considerations for development and manufacturing of personalized cancer vaccines

Cancer & Immunotherapy Vaccines Conference
Apr 1614:40
Conference pass

Utilizing human challenge studies to accelerate the development of respiratory vaccines

Influenza and Respiratory Vaccines
Senior representative, hVIVO
Apr 1614:40
Conference pass

Towards a novel prophylactic vaccine for the prevention of Lyme disease: Development status and outlook

Emerging and Re-emerging Diseases
Apr 1614:40
Conference pass

Got Informatics? Practical Applications of Informatics in Modern Vaccine

Clinical Development and Trials Conference
Darin Seehafer, Project Manager, Product Registration, PRA Health Sciences
Apr 1614:40
Conference pass

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

Bioprocessing & Manufacturing Conference
Apr 1614:40
Conference pass

Precision breeding for animal health: How gene editing will improve our livestock systems

Veterinary Vaccines Conference
Apr 1614:40
Conference pass

Strategies for Effective Partnerships with the US Government, NGOs, International Collaborators and Beyond.

Vaccine Partnerships Conference
Apr 1614:40
Conference pass
Apr 1614:55
Conference pass

Panel: Re-emergence of dendritic cell vaccines for cancer treatment

Cancer & Immunotherapy Vaccines Conference
  • Understanding the mechanisms by which DC functions are disrupted by the tumor microenvironment
  • Insights on innovative improvements in DC targeted vaccine platforms
    • Methods for improving DC maturation, antigen presentation, antigen loading, selection and proliferation
    • Alternatives to using monocyte-derived DCs
  • How can a combination of this and other immunotherapies be used to overturn tumor-induced immune-suppression?
Apr 1615:10
Conference pass

Building further on Viroclinics Ferret model with novel insights: Transmission of HRSV in immunocompromised ferrets

Influenza and Respiratory Vaccines
Reserved for Viroclinics Biosciences
Apr 1615:10
Conference pass

Dengue on trial

Emerging and Re-emerging Diseases
  • Update on efficacy studies of the live attenuated dengue vaccine TV003/005
  • Progress of the Butantan dengue Phase III clinical trial
  • The dengue vaccine program at Merck
  • WHO recommendations for Dengvaxia
Apr 1615:10
Conference pass

Bioprocessing Adenovirus – technical and economic considerations

Bioprocessing & Manufacturing Conference
We will present experimental work and process economy calculations, from AdV production in cell culture to purified bulk productAn efficient and scalable process for AdV production was developed from analysis of each process step
Apr 1615:10
Conference pass

Monoclonal antibodies for companion animal allergic skin diseases

Veterinary Vaccines Conference
Apr 1615:10
Conference pass

Joint presentation: Emerging innovations in vaccine safety science, perspectives from academia and industry

Vaccine Safety Conference
Apr 1615:40
Conference pass

Analysis of the antibody repertoire elicited by viral infection and vaccination to aid the development of more efficient vaccines

Immune Profiling Conference
Apr 1615:40
Conference pass

Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

Influenza and Respiratory Vaccines
Apr 1615:40
Conference pass

Correlates of Protection in Vaccine Clinical Development

Clinical Development and Trials Conference
-From Model Fitting to Machine Learning
Jakub Simon, Director Clinical Research, Merck & Co
Apr 1615:40
Conference pass

The development of low-cost suspension MDCK cell-based production platform for seasonal and pandemic influenza vaccine production

Bioprocessing & Manufacturing Conference
Dr Min-Shi Lee, Associate Investigator, National Health Research Institutes
Apr 1615:40
Conference pass

Deceptive imprinting: A cosmopolitan host immune evading strategy of animal health pathogens

Veterinary Vaccines Conference
Apr 1615:40
Conference pass

Successful case study 1: Sanofi – Translate Bio collaboration to develop mRNA vaccines for multiple infectious diseases

Vaccine Partnerships Conference
-How both companies identified the initial match?-How the responsibilities of each party were determined-Lessons learned so far and what both parties hope to achieve
Apr 1615:55
Conference pass

Vaccinia virus-based immunotherapy for the treatment of solid tumors

Cancer & Immunotherapy Vaccines Conference
Apr 1616:40
Conference pass

Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine

Immune Profiling Conference
Apr 1616:40
Conference pass

Development of safe and effective cancer therapies using approaches based on the measles virus vaccine vector

Cancer & Immunotherapy Vaccines Conference
Apr 1616:40
Conference pass

Structural vaccinology for paramyxoviruses

Influenza and Respiratory Vaccines
Apr 1616:40
Conference pass

The global vector control response: The issue of integrating vaccine with vector control with a focus on new VC technology

Emerging and Re-emerging Diseases
  • Where are we on dengue, malaria, chikungunya, yellow fever and Zika
  • How can vaccines and vector control be integrated and used synergistically and has it worked?
Apr 1616:40
Conference pass

Frontiers in controlled human malaria infection (CHMI): accelerating malaria vaccine development, use in HIV+ populations, and empowering malaria research in Africa

Clinical Development and Trials Conference
-Aseptic, purified, cryopreserved sporozoites for CHMI (“challenge in a bottle”)-Expansion of research capabilities in Africa-Ethical considerations of CHMI in HIV+ populations
Apr 1616:40
Conference pass

Alternative delivery system technology showcase

Bioprocessing & Manufacturing Conference
  • Expanding vaccine effectiveness with needle-free delivery
Dr Marilyn Dysart, Clinical Affairs Manager, PharmaJet
Apr 1616:40
Conference pass

Where is the future in veterinary vaccine delivery?

Veterinary Vaccines Conference
Dr Dale Polson, Lead, Integrated Health Systems, Boehringer Ingelheim Animal Health
Apr 1616:40
Conference pass

Successful case study 2: GSK – DARPA partnership, self-amplifying mRNA vaccine technology

Vaccine Partnerships Conference
-Objectives of a public-private partnership -How were the partners resourced-What was the outcome of the collaboration
Apr 1616:40
Conference pass

Challenges in post-licensure safety studies using real world data. Example: Hepatitis b vaccine

Vaccine Safety Conference
Apr 1616:40
Conference pass

Integrating novel technology and digitalization to improve end-to-end visibility and agility in pharmaceutical supply chains

Supply & Logistics Conference
Reserved
Apr 1616:55
Conference pass

Alternative delivery system technology showcase

Bioprocessing & Manufacturing Conference
  • Clinical milestone in skin vaccination: Combining the P.L.E.A.S.E.® epidermal system with the dry-patch technology boosts immunogenicity in an adjuvant-free setting
Apr 1617:10
Conference pass

Rapidly generated pandemic countermeasures by deep mining of natural immune repertoires

Immune Profiling Conference
Apr 1617:10
Conference pass

GSK’s RSV vaccine pipeline update

Influenza and Respiratory Vaccines
Martina Kovac, Vaccine Development Leader-Maternal Immunization, GSK
Apr 1617:10
Conference pass

How do we move forward in Zika vaccine development using the Human Challenge Model

Clinical Development and Trials Conference
-Bioethics of using the human challenge model-Background information on the original report for zika vaccine development-Epidemiology of zika today-How has the landscape changed
Apr 1617:10
Conference pass

Alternative delivery system technology showcase

Bioprocessing & Manufacturing Conference
  • Microprojection array patch clinical study with influenza vaccine: Demonstration of efficacy, dose reduction, and high temperature stability
Apr 1617:10
Conference pass

Mucosal PRRSV vaccine for swine

Veterinary Vaccines Conference
  • Benefits of administration via nasal spray
  • Vaccine efficacy
  • Summary of field trial data and findings
Session led by: aptimmune-biologics-inc
Apr 1617:10
Conference pass

Understanding what corporate funders and VCs are looking before they invest

Vaccine Partnerships Conference
Apr 1617:10
Conference pass

The state of vaccine safety science; a systematic review of the evidence

Vaccine Safety Conference
Apr 1617:25
Conference pass

The “how’s” of Human Challenge Model studies (CHIMS)

Clinical Development and Trials Conference
-How are the studies done?-How are the models developed and used?-How are CHIMS becoming more commercially used?-Why do subjects volunteer?
Philip Krause, Deputy Director, U.S. Food and Drug Administration
Apr 1617:25
Conference pass

Alternative delivery system technology showcase

Bioprocessing & Manufacturing Conference
Mucosal delivery routes
Apr 1617:40
Conference pass

How do we overcome the challenges of analyzing big molecular biological data?

Immune Profiling Conference
Apr 1617:40
Conference pass

Ongoing development of a novel vaccine for Respiratory Syncytial Virus

Influenza and Respiratory Vaccines
  • An overview of preclinical, phase 1 data and recent phase 2 results
  • Development aspects unique to RSV and immunologic correlates
  • Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval
Apr 1617:40
Conference pass

Expeditionary research in emerging & re-emerging disease: What is it?

Emerging and Re-emerging Diseases
  • Accessing emerging / re-emerging diseases in difficult or remote regions of the world is immensely complex.
  • Learn what expeditionary research is and how to support it (staff, technology, logistics)
  • How do you switch from a briefcase to a backpack
Apr 1617:40
Conference pass

The Delivery Board: Reviewing presentations and their effectiveness

Bioprocessing & Manufacturing Conference
  • How does different routes of delivery influence the immunological outcome?
  • Effectiveness and usability
Apr 1617:40
Conference pass

Orally administered vaccines for poultry

Veterinary Vaccines Conference
Lisa Bielke, Assistant Professor, Ohio State University
Apr 1617:40
Conference pass

How big data can lead to safer drugs and vaccines

Vaccine Safety Conference
Apr 1617:55
Conference pass

Sanofi Pasteur’s RSV prophylactic program

Influenza and Respiratory Vaccines

Create your personal agenda –check the favourite icon

Apr 1709:00
Conference pass
Apr 1709:00
Conference pass

Chair’s opening remarks

Veterinary Vaccines Conference
Apr 1709:10
Conference pass

Targeting specific oncogenic pathways to restore the immune response against cancers

Immune Profiling Conference
Apr 1709:10
Conference pass

DEACT – A unique dual enhanced adoptive cell therapy platform for the treatment of multiple myeloma and solid tumors

Cancer & Immunotherapy Vaccines Conference
Apr 1709:10
Conference pass

Identifying adjuvants that stimulate a protective immune response in Pertussis

Influenza and Respiratory Vaccines
Apr 1709:10
Conference pass

Manufacturing technology showcase: Development of a new manufacturing platform technology for human vaccines

Bioprocessing & Manufacturing Conference
Apr 1709:10
Conference pass

Overcoming the challenges of bacterial vaccine design

Veterinary Vaccines Conference
Apr 1709:10
Conference pass

NIH – Emerging Diseases, Vaccination and Immunization Strategy

Vaccine Partnerships Conference
Apr 1709:10
Conference pass

Safety monitoring of vaccines targeting special populations (e.g. elderly, maternal): Current challenges and approaches

Vaccine Safety Conference
Apr 1709:25
Conference pass

Manufacturing technology showcase: Development of EcoCRM®, a new GMP CRM197 carrier protein

Bioprocessing & Manufacturing Conference
Apr 1709:25
Conference pass

UNICEF – An update on vaccine procurement and global immunization strategy

Vaccine Partnerships Conference
Apr 1709:40
Conference pass

Designing “nanoimmunotherapies” to modify the tumor microenvironment and potentiate robust systemic antitumor immune responses

Immune Profiling Conference
Rohan Fernandes, Assistant Professor, The George Washington University
Apr 1709:40
Conference pass

Development of next generation adoptive cell therapies for solid tumors

Cancer & Immunotherapy Vaccines Conference
Apr 1709:40
Conference pass

Dupilumab imprints a TH1/Type 1 response and enhances the efficacy of the acellular whooping cough vaccine in mice and infant baboons

Influenza and Respiratory Vaccines
Dr Christopher Petro, Scientist, Regeneron
Apr 1709:40
Conference pass

Manufacturing technology showcase

Bioprocessing & Manufacturing Conference
Practical solutions enabling rapid and sustainable productionSenior representation, Paragon
Apr 1709:40
Conference pass

Developing vaccines against bacterial pathogens in animal species and humans using a salmonella vaccine vector platform

Veterinary Vaccines Conference
Apr 1709:40
Conference pass

EDCTP – Public-Private partnership between Europe and sub-Saharan Africa to accelerate the development of vaccines

Vaccine Partnerships Conference
Apr 1709:40
Conference pass

Joint presentation: Challenges in trial design, implementation and safety assessment of an Ebola vaccine under clinical development

Vaccine Safety Conference
Apr 1709:55
Conference pass

A new broad-spectrum vaccine against Streptococcus pneumoniae

Influenza and Respiratory Vaccines
Apr 1709:55
Conference pass

MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine

Influenza and Respiratory Vaccines
Apr 1709:55
Conference pass

NVPO – Priorities and how to improve vaccination system in the US, Adult Immunization, Vaccine Safety

Vaccine Partnerships Conference
Melinda Wharton, Director, Imm Svcs Division, CDC
Apr 1710:10
Conference pass

Utility of minimally invasive sampling in clinical trials

Immune Profiling Conference
Apr 1710:10
Conference pass

Overview of the cell therapy landscape in China

Cancer & Immunotherapy Vaccines Conference
Apr 1710:10
Conference pass

Broad cross-protection and heterologous challenge

Influenza and Respiratory Vaccines
Apr 1710:10
Conference pass

Use of oral cholera vaccine as a key component to eliminate epidemic cholera as a public health threat

Emerging and Re-emerging Diseases
Apr 1710:10
Conference pass

Are bacterial vaccines harder to develop?

Clinical Development and Trials Conference
  • What are the challenges in clinical efficacy trials?
  • Phase II Clostridium difficile vaccine
Apr 1710:10
Conference pass

Manufacturing technology showcase: Scalable in vitro manufacturing of tailored vaccines

Bioprocessing & Manufacturing Conference
Apr 1710:10
Conference pass

Regulatory pathways to enable the licensing of alternatives to antibiotics

Veterinary Vaccines Conference
Apr 1710:10
Conference pass

NVAC – National Vaccine Plan Strategy, Topics affecting Vaccine Enterprise

Vaccine Partnerships Conference
Apr 1710:25
Conference pass

Influenza vaccines immunological assessment

Influenza and Respiratory Vaccines
Apr 1710:25
Conference pass

Manufacturing technology showcase

Bioprocessing & Manufacturing Conference
Affinity chromatography for vaccines purification
Apr 1711:30
Conference pass

Panel: Navigating the engineered cell therapy landscape – prospects and challenges

Cancer & Immunotherapy Vaccines Conference
Dr John Knighton, Vice President of A.P.I. Large Molecule Development, Janssen Research & Development, LLC
Dr Aisha Hasan, Clinical Development Head, Oncology Cell and Gene Therapy, Glaxo Smith Kline
Apr 1711:30
Conference pass

The path to controlling the Global HIV pandemic; the roles of antiretrovirals and preventive vaccines

Emerging and Re-emerging Diseases
Apr 1711:30
Conference pass

Broad spectrum pneumococcal conjugate vaccines in development

Clinical Development and Trials Conference
Apr 1711:30
Conference pass

Establishing a One Health approach to combat emerging zoonotic & transboundary diseases

Veterinary Vaccines Conference
Apr 1711:30
Conference pass

How to expand vaccine development of neglected diseases to a truly international level

Vaccine Partnerships Conference
Representatives from: Europe, Africa, Mexico, Saudi, South America- Challenges and disease targets of each market- Funding opportunities - Perspective partnerships
Apr 1711:30
Conference pass

Considerations for safety assessment of a new class of mRNA vaccines

Vaccine Safety Conference
Apr 1711:45
Conference pass

PREDICT project: Detection and discovery of zoonotic diseases at the wildlife-human interface

Veterinary Vaccines Conference
Apr 1712:00
Conference pass

Biomarker strategies for patient selection

Immune Profiling Conference
Apr 1712:00
Conference pass

GAS vaccine development

Emerging and Re-emerging Diseases
Apr 1712:00
Conference pass

Expectations and CMC strategies for infectious disease monoclonal antibodies

Bioprocessing & Manufacturing Conference
Apr 1712:00
Conference pass

New tools to combat Respiratory PRRS

Veterinary Vaccines Conference
Apr 1712:00
Conference pass

Adversomics: a glimpse into the future

Vaccine Safety Conference
Apr 1712:15
Conference pass

African Swine Fever – Still no vaccine, updates on how the animal health industry is targeting this disease?

Veterinary Vaccines Conference
Apr 1713:30
Conference pass
Apr 1713:40
Conference pass

New lessons from old controversies

Keynotes
  • What have we learnt from previous vaccines failures to drive new vaccines forward?
  • Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
  • Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
Apr 1714:55
Conference pass

A framework for a comprehensive maternal immunization platform

Keynotes
  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Apr 1715:25
Conference pass

What is the status of the development pipeline for infectious disease vaccines in the US? Trends and implications for the future

Keynotes
  • An industry pipeline dissection
  • Which type of companies are engaged in these programs?
  • Where will the innovation come from?
  • Incentives, insights and potential solutions
last published: 21/Mar/19 15:26 GMT

 

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071